| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Alpha-Adenosine targets adenosine A1 receptors, which are G protein-coupled receptors involved in the regulation of heart rate, neurotransmission, and vascular tone. As a purine nucleoside analog, it has broad antitumor activity targeting indolent lymphoid malignancies. The compound's mechanism involves activation or modulation of adenosine receptor signaling pathways. Alpha-adenosine is an isomer of adenosine with potential therapeutic applications in cardiovascular and neurological disorders.
|
|---|---|
| ln Vitro |
Alpha-Adenosine demonstrates in vitro activity as a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. The compound's activity is typically assessed in cellular assays measuring cell proliferation, viability, and apoptosis in cancer cell lines. As an adenosine A1 receptor ligand, its activity can be assessed in receptor binding and signaling assays. Alpha-adenosine has been investigated for potential therapeutic applications.
|
| ln Vivo |
In vivo studies for Alpha-Adenosine have not been extensively documented in the available literature. As an adenosine A1 receptor ligand, it has potential for in vivo applications in cardiovascular and neurological disorders. Studies in appropriate animal models would be needed to evaluate its in vivo efficacy, pharmacokinetics, and safety profile. The compound has been investigated for potential therapeutic applications in arrhythmias, stroke, and neurodegenerative diseases.
|
| Enzyme Assay |
For adenosine A1 receptor binding assays, Alpha-Adenosine is tested against A1 receptors at various concentrations. Binding affinity is measured using radioligand binding assays with [3H]- or [125I]-labeled ligands. IC50 or Ki values are calculated from dose-response curves. For cellular assays, cells expressing A1 receptors are treated with the compound and downstream signaling (e.g., cAMP levels) is measured.
|
| Cell Assay |
For cellular studies, appropriate cancer cell lines are cultured in appropriate media and treated with Alpha-Adenosine at various concentrations. Cells are incubated for 24-72 hours, and cell viability is assessed using MTT or CellTiter-Glo assays. IC50 values are calculated from dose-response curves. Apoptosis induction is assessed by caspase-3/7 activity or Annexin V staining. For adenosine receptor studies, cells expressing A1 receptors are treated with the compound and cAMP levels are measured.
|
| Animal Protocol |
For in vivo efficacy studies, appropriate animal models of cancer, cardiovascular disease, or neurological disorders would be used. Alpha-Adenosine would be administered via appropriate routes at various doses. Tumor volume, cardiac function, or neurological outcomes would be assessed. Pharmacokinetic parameters including half-life, clearance, and tissue distribution would be determined. However, detailed in vivo protocols for Alpha-Adenosine have not been extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Alpha-Adenosine have not been fully characterized in the available literature. The compound has a molecular formula of C10H13N5O4 and a molecular weight of 267.24. Purity is 99%. It is a purine nucleoside analog. Comprehensive PK studies including bioavailability, half-life, protein binding, and tissue distribution are needed to fully understand its ADME properties.
|
| Toxicity/Toxicokinetics |
Alpha-Adenosine is a research compound intended for laboratory use only and is not approved for human therapeutic use. As a purine nucleoside analog and adenosine A1 receptor ligand, it has been investigated for potential therapeutic applications in arrhythmias, stroke, and neurodegenerative diseases. Standard laboratory safety precautions should be followed when handling this compound. Purity 99%.
|
| References | |
| Additional Infomation |
Alpha-Adenosine is a purine nucleoside analog with molecular formula C10H13N5O4 and molecular weight 267.24. It is an isomer of adenosine that binds to A1 receptors involved in heart rate regulation, neurotransmission, and vascular tone. The compound has been investigated for potential therapeutic applications in arrhythmias, stroke, and neurodegenerative diseases. It is for research use only and has not been approved for clinical applications. Purity 99%.
|
| Molecular Formula |
C10H13N5O4
|
|---|---|
| Molecular Weight |
267.24
|
| Exact Mass |
267.097
|
| CAS # |
5682-25-7
|
| PubChem CID |
447270
|
| Appearance |
Off-white to light yellow solid powder
|
| Melting Point |
205-207 °C
|
| LogP |
-1.1
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
335
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=NC(=C2C(=N1)N(C=N2)[C@@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N
|
| InChi Key |
OIRDTQYFTABQOQ-CRKDRTNXSA-N
|
| InChi Code |
InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10+/m1/s1
|
| Chemical Name |
(2S,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 250 mg/mL (935.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7420 mL | 18.7098 mL | 37.4195 mL | |
| 5 mM | 0.7484 mL | 3.7420 mL | 7.4839 mL | |
| 10 mM | 0.3742 mL | 1.8710 mL | 3.7420 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
